Novo Nordisk ups outlook fuelled by obesity drug demand
Novo Nordisk has today raised its 2024 outlook and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly.